Literature DB >> 10940688

Natural history of neuroendocrine enteropancreatic tumors.

M Mignon1.   

Abstract

Neuroendocrine enteropancreatic tumors (NEEPTs) include tumors developing from the pancreatic islets and the duodenal loop, and those developing from gut serotonin-secreting cells (mid-gut carcinoids). When functioning, they are rare tumors with frequently inconsistant clinical and biological characteristics. Provocative dynamic tests are very useful. Their natural history, with the exception of insulinomas and mid-gut carcinoids, is still incompletely known due to their rarity, relatively recent description, slow evolution and the absence of definitive reliable markers for prognosis. The following factors affect the natural history of NEEPTs. (1) Inclusion or not within the spectrum of multiple endocrine neoplasia type-1 (MEN1), such an integration often dramatically modifies the management strategy. In patients with MEN1, NEEPTs are often multiple, diffusely spread in the duodenopancreatic area and of small size. Definite cure by surgery is then very scarce. Mid-gut carcinoid tumors are the most protean NEEPTs. In contrast to appendiceal carcinoids, usually with a benign course, mid-gut carcinoids have a more malignant course and are very common indeed: local transmural invasion, early metastasis to lymph nodes and/or liver, and symptoms from hormone oversecretion. Carcinoid syndrome is usually well controlled by long-acting somatostatin analogs. (2) Disease spreading, i.e. liver and bone metastases, are the major causes of death in patients with NEEPTs. Liver metastases (LMs) are synchronous in about 75% of the patients with LMs but may develop during follow-up (about 25% of the patients with LMs were without LMs at the initial evaluation). Development of bone metastases has a very poor prognosis accompanying LM progression. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 10940688     DOI: 10.1159/000051856

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  21 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 2.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

Review 3.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

4.  Imaging of gastroenteropancreatic neuroendocrine tumors.

Authors:  Eik Hock Tan; Cher Heng Tan
Journal:  World J Clin Oncol       Date:  2011-01-10

5.  Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.

Authors:  Mitsuru Sugimoto; Tadayuki Takagi; Takuto Hikichi; Rei Suzuki; Ko Watanabe; Jun Nakamura; Hitomi Kikuchi; Naoki Konno; Yuichi Waragai; Hiroyuki Asama; Mika Takasumi; Hiroshi Watanabe; Katsutoshi Obara; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 6.  Multiple endocrine neoplasia type 1 revealed by a hip pathologic fracture.

Authors:  Maroua Slouma; Maissa Abbes; Rim Dhahri; Noureddine Litaiem; Nour Gueddiche; Nada Mansouri; Issam Msekni; Imen Gharsallah; Leila Metoui; Bassem Louzir
Journal:  Clin Rheumatol       Date:  2020-07-14       Impact factor: 2.980

Review 7.  Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Fathia Gibril; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2005-05

Review 8.  Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.

Authors:  Krystallenia I Alexandraki; Gregory Kaltsas
Journal:  Endocrine       Date:  2011-11-29       Impact factor: 3.633

Review 9.  Minimally invasive pancreatic surgery: the new frontier?

Authors:  Basil J Ammori; Saleh Baghdadi
Journal:  Curr Gastroenterol Rep       Date:  2006-04

10.  Lymph nodes and survival in pancreatic neuroendocrine tumors.

Authors:  Geoffrey W Krampitz; Jeffrey A Norton; George A Poultsides; Brendan C Visser; Lixian Sun; Robert T Jensen
Journal:  Arch Surg       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.